NICE Gives Thumbs Down to Simponi--For Now
The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.
The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.